AMENDMENT NUMBER ONE TO DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT Amendment Effective Date: January 18, 2016

This Amendment Number One to Development Collaboration and License Agreement (this “Amendment”) is entered into effective as of January 18, 2016 (the “Amendment Effective Date”) by and among Clinical Micro Sensors, Inc. d.b.a. GenMark Diagnostics, Inc., a Delaware corporation having a principal place of business at 5964 La Place Court, Carlsbad, CA 92008 (“GenMark”), Advanced Liquid Logic, Inc., a Delaware corporation having its principal place of business at 5200 Illumina Way, San Diego, CA 92122 (“ALL”), and Illumina, Inc., a Delaware corporation having a principal place of business at 5200 Illumina Way, San Diego, CA 92122 (“Illumina”). GenMark, ALL and Illumina are hereinafter and in the Agreement (as defined below) referred to individually as a “Party” and collectively as the “Parties” (subject to the qualification below relating to Illumina). Capitalized terms used but not defined herein shall have the meaning given to such terms in the Agreement.

“4.4    Transition of Manufacturing Know-How. The Parties shall cooperate in good faith and diligently perform, and exercise their reasonable best efforts to complete no later than ***, the respective activities assigned to and/or reasonably contemplated to be performed by each Party as described in the technology transfer plan executed by the Parties concurrently herewith (the “Technology Transfer Plan”). The Technology Transfer Plan shall require ALL and Illumina to, and ALL and Illumina shall, transfer to GenMark all Technical Information and Materials in ALL’s and/or Illumina’s (and their Affiliates’) possession that, as of the Amendment Effective Date, are used by ALL and/or Illumina (and their Affiliates) in connection with the manufacture of ALL Components that are “Products” as defined in the Supply Agreement (all of which constitute ALL IP Rights or Joint Collaboration IP Rights); and no information or materials that are not used in connection with the manufacture of such “Products” shall be part of the activities under the Technology Transfer Plan (“Technology Transfer”). The Technology Transfer Plan reflects both Parties’ reasonable, good faith estimates of the time commitments and activities required to achieve a successful Technology Transfer. The reasonable, good faith time estimates set forth in the Technology Transfer Plan shall not be exceeded without the Parties’ prior written consent, which shall not be unreasonably withheld or conditioned. Each Party shall ensure that personnel appropriate for the tasks then being undertaken, in terms of their seniority, availability and function in their respective organizations, training and experience, including in respect of manufacturing,

operations, and quality and process transfer expertise, are adequately involved in performing the activities described in the Technology Transfer Plan. The Parties acknowledge and agree that ALL’s and Illumina’s obligations to perform the activities assigned to ALL and Illumina set forth in the Technology Transfer Plan shall terminate on *** (the “Transfer Termination Date”); provided that Illumina and ALL have complied with all of their respective obligations and have diligently performed all activities assigned to ALL and Illumina as set forth in the Technology Transfer Plan by such date (unless, but only to the extent, any delays or failures are directly due to acts or omissions of GenMark). Notwithstanding the foregoing, if Illumina and/or ALL have failed to fulfill any of their obligations or diligently perform any of the activities assigned to ALL or Illumina in the Technology Transfer Plan by ***, then the Transfer Termination Date and ALL’s and Illumina’s obligations to perform under the Technology Transfer Plan shall continue until such time as all such obligations have been satisfied and all such activities have been completed in full (unless, but only to the extent, any delays or failures are directly due to acts or omissions of GenMark). GenMark shall reimburse ALL and Illumina for *** of the direct costs (determined in accordance with GAAP) incurred by ALL and Illumina for activities properly undertaken pursuant to the Technology Transfer Plan.”

“4.5    Royalties. In each Calendar Quarter during the Term of this Agreement in which GenMark records Net Sales of a Consumable Licensed Product that contains ALL Components that are manufactured by GenMark or otherwise not manufactured and supplied pursuant to the Supply Agreement (“GenMark Manufactured Consumables”), GenMark shall pay to ALL (or to an Affiliate of ALL if GenMark is notified in writing by ALL or an ALL Affiliate), subject to Section 6.11, an amount equal to ***% of Net Sales of GenMark Manufactured Consumables during such Calendar Quarter. For the avoidance of doubt, GenMark shall not be required to pay any Additional Margin under the Agreement.”

“6.7    Royalties on Instrument Licensed Products. GenMark *** for Net Capital Sales of Instrument Licensed Products Covered by a Valid Claim.”

“6.8    Transfer Price of ALL Components. The price of ALL Components supplied by ALL and/or Illumina to GenMark under the Supply Agreement shall be as set forth in the Supply Agreement only.”

“6.11     Deductions from Payments. If GenMark has obtained or in the future obtains a license or immunity from an infringement suit from any Third Party pursuant to which GenMark, its Affiliates, distributors or Sublicensees is/are required to pay to any Third Party any fee, royalty or other payment in connection with a right or license under any Third Party intellectual property rights to make, have made, use, offer for sale, sell or import Licensed Products, GenMark shall have the right to set off any and all amounts paid to such Third Party, including fee, royalty or other payments, against payment of the royalty payments otherwise payable hereunder; provided that in no event shall royalties otherwise payable to ALL and/or an ALL Affiliate hereunder be reduced to less than *** of Net Sales of GenMark Manufactured Consumables during each Calendar Quarter during the Term of this Agreement in which GenMark records Net Sales of GenMark Manufactured Consumables. Such right of offset shall be in addition to, and not in lieu of, any other rights or claims GenMark may have under this Agreement or otherwise.”

“During the Development Term and the remainder of the Term of this Agreement, ALL shall, upon GenMark’s written request, but in any event no more frequently than once every six (6) months, disclose to GenMark all Patents within the ALL IP Rights (including in each case, any such Patents of which ALL acquires Control after the Effective Date).”

Clinical Micro Sensors, Inc.,